Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04EGX
|
|||
| Former ID |
DAP000251
|
|||
| Drug Name |
Cabergoline
|
|||
| Synonyms |
Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperprolactinaemia [ICD-11: 5A60.1; ICD-10: E22.1; ICD-9: 253.1] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Pfizer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H37N5O2
|
|||
| Canonical SMILES |
CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
|
|||
| InChI |
1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
|
|||
| InChIKey |
KORNTPPJEAJQIU-KJXAQDMKSA-N
|
|||
| CAS Number |
CAS 81409-90-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10387, 7848050, 7978840, 8183775, 12013713, 14759961, 14808642, 34718715, 46508571, 48415679, 49965419, 53787199, 57313654, 75968790, 85788035, 92309005, 92713133, 92740959, 93166933, 103771070, 104305757, 117539013, 118047283, 126624984, 126656189, 126684133, 134337565, 135013805, 135652674, 135989394, 137001464, 142175117, 144206142, 152101006, 160963596, 162179026, 163133315, 164155372, 164824353, 170464667, 175267048, 176484246, 179151225, 184546096, 196111573, 223682255, 223820795, 226427091, 252222293, 252391240
|
|||
| ChEBI ID |
CHEBI:3286
|
|||
| ADReCS Drug ID | BADD_D00329 | |||
| SuperDrug ATC ID |
G02CB03; N04BC06
|
|||
| SuperDrug CAS ID |
cas=081409907
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 37). | |||
| REF 2 | Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. | |||
| REF 3 | Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7. | |||
| REF 4 | Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J Neurol Sci. 2009 Mar 15;278(1-2):44-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.